KalVista Pharmaceuticals (KALV) Capital Expenditures (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Capital Expenditures of $147000.0 in Q3 2025, down 57.02% quarter-over-quarter from $342000.0 in Q2 2025, and up 129.69% year-over-year from $64000.0 in Q3 2024.
KalVista Pharmaceuticals' Capital Expenditures history runs 12 years deep, the most recent figure standing at $147000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures rose 129.69% year-over-year to $147000.0; the TTM figure through Jul 2025 stood at $618000.0 (up 518.0% YoY), while the FY2025 annual figure was $495000.0, up 1078.57% from the prior year.
- Capital Expenditures came in at $147000.0 for Q3 2025 at KalVista Pharmaceuticals, down from $342000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $920000.0 in Q3 2022 to a low of -$252000.0 in Q2 2024.
- A 5-year average of $157444.4 and a median of $77500.0 in 2022 frame the typical range for Capital Expenditures.
- On a YoY basis, Capital Expenditures climbed as much as 3150.0% in 2024 and fell as far as 465.22% in 2024.
- KalVista Pharmaceuticals' Capital Expenditures stood at $356000.0 in 2021, then plunged by 46.07% to $192000.0 in 2022, then plunged by 98.96% to $2000.0 in 2023, then jumped by 3150.0% to $65000.0 in 2024, then jumped by 126.15% to $147000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $147000.0, $342000.0, and $65000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 147,000.00 |
| Jul 31, 2025 | 147,000.00 |
| Apr 30, 2025 | 342,000.00 |
| Apr 30, 2025 | 342,000.00 |
| Oct 31, 2024 | 65,000.00 |
| Oct 31, 2024 | 65,000.00 |
| Jul 31, 2024 | 64,000.00 |
| Jul 31, 2024 | 64,000.00 |
| Apr 30, 2024 | -252,000.00 |
| Apr 30, 2024 | -252,000.00 |
| Jan 31, 2024 | 286,000.00 |
| Jan 31, 2024 | 286,000.00 |
| Oct 31, 2023 | 2,000.00 |
| Oct 31, 2023 | 2,000.00 |
| Jul 31, 2023 | 6,000.00 |
| Jul 31, 2023 | 6,000.00 |
| Apr 30, 2023 | 69,000.00 |
| Apr 30, 2023 | 69,000.00 |
| Jan 31, 2023 | 15,000.00 |
| Jan 31, 2023 | 15,000.00 |
| Oct 31, 2022 | 192,000.00 |
| Oct 31, 2022 | 192,000.00 |
| Jul 31, 2022 | 920,000.00 |
| Jul 31, 2022 | 920,000.00 |
| Apr 30, 2022 | 86,000.00 |
| Apr 30, 2022 | 86,000.00 |
| Jan 31, 2022 | 202,000.00 |
| Jan 31, 2022 | 202,000.00 |
| Oct 31, 2021 | 356,000.00 |
| Oct 31, 2021 | 356,000.00 |
| Jul 31, 2021 | 287,000.00 |
| Jul 31, 2021 | 287,000.00 |
| Apr 30, 2021 | 33,000.00 |
| Apr 30, 2021 | 33,000.00 |
| Jan 31, 2021 | 14,000.00 |
| Jan 31, 2021 | 14,000.00 |
| Oct 31, 2020 | 13,000.00 |
| Oct 31, 2020 | 13,000.00 |
| Jul 31, 2020 | 22,000.00 |
| Jul 31, 2020 | 22,000.00 |
| Apr 30, 2020 | 8,000.00 |
| Apr 30, 2020 | 8,000.00 |
| Oct 31, 2019 | 114,000.00 |
| Oct 31, 2019 | 114,000.00 |
| Jul 31, 2019 | 98,000.00 |
| Jul 31, 2019 | 98,000.00 |
| Apr 30, 2019 | 275,000.00 |
| Apr 30, 2019 | 275,000.00 |
| Jan 31, 2019 | 20,000.00 |
| Jan 31, 2019 | 20,000.00 |
| Oct 31, 2018 | 221,000.00 |
| Oct 31, 2018 | 221,000.00 |
| Jul 31, 2018 | 565,000.00 |
| Jul 31, 2018 | 565,000.00 |
| Apr 30, 2018 | 1.08 Mn |
| Apr 30, 2018 | 1.08 Mn |
| Jan 31, 2018 | 182,000.00 |
| Jan 31, 2018 | 182,000.00 |
| Oct 31, 2017 | 51,000.00 |
| Oct 31, 2017 | 51,000.00 |
| Jul 31, 2017 | 110,000.00 |
| Jul 31, 2017 | 110,000.00 |
| Apr 30, 2017 | 7,000.00 |
| Apr 30, 2017 | 7,000.00 |
| Jan 31, 2017 | 6,000.00 |
| Jan 31, 2017 | 6,000.00 |
| Oct 31, 2016 | 18,000.00 |
| Oct 31, 2016 | 18,000.00 |
| Jul 31, 2016 | 43,000.00 |
| Jul 31, 2016 | 43,000.00 |
| Mar 31, 2016 | 184,000.00 |
| Mar 31, 2016 | 184,000.00 |
| Dec 31, 2015 | 379,000.00 |
| Dec 31, 2015 | 379,000.00 |
| Sep 30, 2015 | 21,000.00 |
| Sep 30, 2015 | 21,000.00 |
| Jun 30, 2015 | 79,000.00 |
| Jun 30, 2015 | 79,000.00 |
| Mar 31, 2015 | 180,000.00 |
| Mar 31, 2015 | 180,000.00 |
| Sep 30, 2014 | 7,000.00 |
| Sep 30, 2014 | 7,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 1,000.00 |
| Mar 31, 2014 | 1,000.00 |